Anonymous
Guest
Anonymous
Guest
He's correct. The potency of a HCV regimen has nothing to do with the number of drugs. It has to do with the amount of viral load decay that can be achieved. I think the 3DAA messaging is faulty. We can't claim our results are better than Gilead's. Why else would we need Ritonavir and RBV? Look at PEARL-4. 90% in GT1a naives without RBV. Harvoni was 99% in ION-1, only one relapse in the 12 week, no RBV arm.
So what was your response to the Provider when he told you 3D is not more potent than Harvoni?
I asked him what are some of the differentiating factors. His response.... Price and managed care.